Summary
No substantive alignment can be evaluated for the listed pricing and opioid-use-disorder claims because the provided FDA label excerpts are only about SECUADO in elderly patients with dementia-related psychosis and state it is not approved for that use; none of the listed claims are supported or contradicted by the provided label content.
Category Scores
Accurate Statements
Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death, and SECUADO is not approved for dementia-related psychosis.
Provided excerpts in sections 5.1 and 8.5 state increased risk of death and that SECUADO is not approved for dementia-related psychosis.
Unsupported Statements
Secuado is a brand of buprenorphine.
The provided prescribing information excerpts concern SECUADO and dementia-related psychosis; no support is provided for buprenorphine or opioid-use-disorder indications.
Secuado is used for opioid use disorder.
No support in the provided prescribing information excerpts.
The exact price of Secuado varies by country.
No pricing guidance is provided in the supplied prescribing information excerpts.
The exact price of Secuado varies by pharmacy.
No pricing guidance is provided in the supplied prescribing information excerpts.
The exact price of Secuado varies by dose strength.
No pricing guidance is provided in the supplied prescribing information excerpts.
The exact price of Secuado varies by insurance coverage.
No pricing guidance is provided in the supplied prescribing information excerpts.
Final cost for Secuado is driven by dose/strength and pack size.
No pricing guidance is provided in the supplied prescribing information excerpts.
Final cost for Secuado is driven by whether the patient has commercial insurance, Medicaid, or Medicare.
No pricing guidance is provided in the supplied prescribing information excerpts.
Final cost for Secuado is driven by copay type (fixed copay versus coinsurance).
No pricing guidance is provided in the supplied prescribing information excerpts.
Final cost for Secuado may be driven by availability of manufacturer programs or pharmacy discounts.
No pricing guidance is provided in the supplied prescribing information excerpts.
Final cost for Secuado is driven by country and local pricing rules.
No pricing guidance is provided in the supplied prescribing information excerpts.
Secuado is buprenorphine.
No support in the provided prescribing information excerpts.
Secuado is a different formulation than Suboxone.
No support in the provided prescribing information excerpts.
Pricing for Secuado is typically not directly interchangeable with Suboxone.
No support in the provided prescribing information excerpts.
Secuado and Suboxone are separate products with separate list prices and reimbursement rules.
No support in the provided prescribing information excerpts.
Common cost-lowering options include asking the pharmacy for the cash price and any discount card they support.
No pricing/cost-sharing guidance is provided in the supplied prescribing information excerpts.
Common cost-lowering options include checking for an on-label patient assistance or copay support program in the country.
No pricing/cost-sharing guidance is provided in the supplied prescribing information excerpts.
Common cost-lowering options include switching to a different covered option if the prescriber allows it.
No pricing/coverage guidance is provided in the supplied prescribing information excerpts.
Insurance may prefer certain formulations.
No pricing/coverage guidance is provided in the supplied prescribing information excerpts.
Contradictions
Low
AI Statement
Secuado is a brand of buprenorphine.
Label Reference
Label excerpts provided state SECUADO is asenapine transdermal system (and contain warnings about dementia-related psychosis; no buprenorphine content is present).
Important Omissions
No label-supported dosing, contraindications, adverse reactions, monitoring, interactions, or administration instructions were evaluated against the cited label excerpts for the majority of listed claims (which are pricing and opioid-use-disorder-related).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported safety claim provided concerns increased mortality risk in elderly patients with dementia-related psychosis and non-approval for that indication. Most other claims are pricing/indication-related and not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims (buprenorphine/opioid use disorder and pricing dynamics) are not supported by the provided FDA label excerpts, which only address dementia-related psychosis warnings for SECUADO.
Suggested Improvement
Limit statements to what is supported by the provided label text (e.g., increased mortality risk and that SECUADO is not approved for dementia-related psychosis) and remove unsupported pricing/opioid-use-disorder content.